

# Post Infarct Left Ventricular Remodeling: Current Concept in Pathophysiology and Management

NA Chowdhury, M Ullah, S Gafur, Z Islam

Department of Cardiology, NICVD, Dhaka.

(*Cardiovasc. j.* 2011; 3(2): 248-253)

## Introduction:

Ventricular remodeling is the process by which ventricular size, shape and function are regulated by mechanical, neurohormonal and genetic factors.<sup>1</sup> Remodeling may be physiological and adaptive during normal growth or pathological due to acute myocardial infarction (AMI), cardiomyopathy, hypertension or valvular heart disease. This article will review left ventricular (LV) remodeling after acute myocardial infarction, pathophysiological mechanisms and therapeutic interventions.

## Pathophysiology:

Postinfarction left ventricular remodeling:

The cardiac myocyte is the major cell involved in remodeling; fibroblasts, collagen, the interstitium and the coronary vessels to a lesser extent also play a role. The cardiomyocyte is terminally differentiated and develops tension by shortening. The extra cellular matrix provides a stress-tolerant, viscoelastic scaffold consisting of type I and type III collagen that couples myocytes and maintains the spatial relations between the myofilaments and their capillary microcirculation. The collagen framework couples adjacent myocytes by intercellular status that align myofilaments to optimize force development, distribute force evenly to the ventricular walls, and prevent sarcomeric deformation.

Myocardial infarction cause acute inflammation in the infarct zone and hemodynamic abnormality. Acute inflammatory reaction causes the migration of macrophages, monocytes, and neutrophils into the infarct zone; this initiates intracellular signaling and neurohormonal activation. The loss

of myocardium due to acute myocardial infarction results in diminished systolic performance and stroke volume. Changes in circulatory hemodynamics are determined primarily by the degree of myocyte loss, the stimulation of the sympathetic nervous system and renin angiotensin aldosterone system and the release of natriuretic peptides. These factors initiate and subsequently modulate reparative changes, which include dilatation hypertrophy and the formation of a discrete collagen scar. Ventricular remodeling may continue for weeks or months until the distending forces are counterbalanced by the tensile strength of the collagen scar. This balance is determined by the size, locations and transmural extent of the infarct, the extent of myocardial stunning, the patency of the infarct-related artery and local trophic factors.<sup>1,2</sup>

Postinfarction remodeling has been arbitrarily divided into an early phase (within 72 hours) and a late phase (beyond 72 hours).

- i) Early remodeling
- ii) Late remodeling

## Early Remodeling:

The early phase involves expansion of the infarct zone,<sup>3</sup> which may result in early ventricular rupture or aneurysm formation. Infarct expansion results from the degradation of the intermyocyte collagen struts by serine proteases and the activation of matrix metalloproteinases (MMPs) released from neutrophils. Infarct expansion occurs within hours of myocyte injury, results in wall thinning and ventricular dilation and causes the elevation of diastolic and systolic wall stresses. Increased wall stress is a powerful stimulus for hypertrophy mediated by mechanoreceptors and

transduced to intracellular signaling, partly via angiotensin II (Ang II) release, which initiates the increased synthesis of contractile assembly units. Adaptive responses are invoked that preserve stroke volume by involving the noninfarcted remote myocardium. Infarct expansion causes the deformation of the border zone and remote myocardium, which alters Frank / Starling relations and augments shortening. Perturbations in circulatory hemodynamics trigger the sympathetic adrenergic system, which stimulates catecholamine synthesis by the adrenal medulla and spillover from sympathetic nerve terminals, activates the renin-angiotensin-aldosterone system and stimulates the production of atrial and brain natriuretic peptides (ANP and BNP). Augmented shortening and increased heart

rate from sympathetic stimulation result in hyperkinesis of the noninfarcted myocardium and temporary circulatory compensation. In addition, the natriuretic peptides reduce intravascular volume and systemic vascular resistance, normalize ventricular filling, and improve pump function.

#### **Late Remodeling:**

Late remodeling involves the left ventricle globally. The failure to normalize increased wall stresses results in progressive dilatation, recruitment of border zone myocardium into the scar, and deterioration in contractile function. Remodeling involves myocyte hypertrophy and alterations in ventricular architecture to distribute the increased wall stresses more evenly as the extra-cellular matrix forms a collagen scar to stabilize the distending forces and prevent further deformation. Myocyte hypertrophy is demonstrable microscopically, with and up to 150% increase in cell volume and mural hypertrophy by in series sarcomeric replication, without a change in sarcomere length.

#### **Remodeling and Hypertrophy:**

Myocyte hypertrophy is an adaptive response during postinfarction remodeling that offsets increased load, attenuates progressive dilatation and stabilizes contractile function. Hypertension after infarction activates the renin-angiotensin system (RAS) aldosterone axis, catecholamine production by adrenal medulla, the spillover from

sympathetic nerve terminals and the secretion of natriuretic peptides. Enhanced norepinephrine (NE) release contributes directly and indirectly to the hypertrophic response. Stimulation of  $\beta_1$  adrenoreceptor by NE leads to myocyte hypertrophy via the Gq-dependent signaling pathway.<sup>7</sup> The activation of  $\beta_1$  adrenoreceptors in the juxtaglomerular apparatus induces renin release, which enhances the production of Ang II. Increased Ang II production, induced by the diminished stretch activation of vascular smooth muscle cells in the juxtaglomerular apparatus, promotes the presynaptic release of NE and blocks its reuptake, increases catecholamine synthesis, and potentiates the postsynaptic action of NE. In addition, Ang II and NE may augment ET-1 release, which is another stimulus for myocyte hypertrophy and stimulates the secretion of ANP. ANP in turn, inhibits the production of catecholamines, Ang II, ET-1 and aldosterone.

These changes enhance local Angiotensin II production, which is the likely stimulus for

hypertrophy in noninfarcted myocardium. In addition to the activation of the RAS and adrenergic receptors locally, small mechanical strains induced by elevated wall stresses sensed by infarcted and noninfarcted myocardium have been implicated in hypertrophy.<sup>7</sup>

Mechanical stretch results in the secretion of Angiotensin II from cytoplasmic granules, and this stretch-induced hypertrophic response is mediated by ATI receptors.<sup>8,9</sup>

Finally activation of calcium-dependent tyrosine kinase, activation of protein kinase, and mitogen-activated (MAP) kinase, and S6 kinase all induce secretion of Angiotensin II. Myocyte hypertrophy of myocytes both at infarcted zone and in noninfarcted areas is the major factor for remodeling of the heart.

#### **Collagen Degradation:**

Collagen breakdown begins within 3 hours of infarction and is induced by serine proteases such as plasmin and the release of MMP8 from neutrophils.<sup>4</sup> The initial digestion of collagen intercellular struts is responsible for the slippage of the necrotic myofilaments that causes infarct expansion.<sup>3</sup> PKC has been implicated in the induction of MMP transcription in that Ang II, ET-

1, tumor necrosis factor, and catecholamines, which cause receptor mediated increases in PKC are associated with an increase in MMPs.

Collagenolytic activity is confined to regions of injury by tissue inhibitors of the metalloproteinases (TIMPs). These low-molecular-weight proteins (TIMPs) form high-affinity complexes with activated MMPs and neutralize collagen degradation by blocking the catalytic domain of MMPs.<sup>10</sup> TIMPs are induced in the infarct zone within 6 hours, peak by day 2, and return to normal by 14 days.<sup>4</sup>

### Triggers for Tissue Repair:

Myocardial repair is triggered by cytokines released from injured myocytes. The cytokine TGF- $\beta$ 1 increases early in the infarct zone, stimulating macrophage and fibroblast chemotaxis and fibroblast proliferation. An increase in interferon activates macrophages to produce nitric oxide, which increases vascular permeability and confines the cellular inflammatory response to the infarct zone.<sup>11</sup> Activated macrophages are genetically transformed to express ACF which provides a local source of Ang II that is regulated independently of plasma Ang II but plays a pivotal role in reparative fibrosis. The early release of TGF- $\beta$ 1 from necrotic myocytes and macrophages is also important in the phenotypic transformation of interstitial fibroblasts to myofibroblasts, which elaborated receptors to Ang II, TGF- $\beta$ 1, and ET-1.

Synthesis of collagen types 1 and 3 by myofibroblasts is modulated by several factors, including Ang II-related mechanical deformation, fibroblast growth factor, platelet-derived growth factor, ANP and bradykinin-mediated prostaglandin E2 and nitric oxide release. By inhibiting fibroblast growth ANP may retard collagen synthesis and limit proliferative remodeling.<sup>12</sup>

Aldosterone is synthesized by myofibroblasts and has concentration in the heart that is >17-fold greater than that in plasma.<sup>13</sup> Aldosterone, which is regulated by nitric oxide, ANP and Ang II stimulates the transcription of collagen type I and type III mRNA. This action is blocked by spironolactone which implicates the mineralocorticoid receptor in collagen synthesis.

Deposition of type III and type I collagen occurs predominantly in the infarct zone; however, it also

occurs in noninfarcted myocardium when intercellular signaling is potentiated by extensive myocyte necrosis. Type III collagen mRNA increases by day 2 and remains elevated for 3 weeks; type I collagen mRNA increases by day 4 and may remain elevated for up to 3 months. Collagen is detectable microscopically by day 7 and then increases dramatically, such that by 28 days, the necrotic myocytes are entirely replaced by fibrous tissue.<sup>4</sup> After the formation of a scar that equalizes distending and restraining forces, collagen formation is down regulated and most myofibroblasts undergo apoptosis.

### Therapeutic Interventions

The effects of therapies designed to prevent or attenuate postinfarction left ventricular remodeling are best considered with reference to the pathophysiological mechanisms involved.

### Thrombolysis

Thrombolysis is of proven value in the acute myocardial infarction, in which the primary objectives are limiting infarct size and salvaging ischemic myocardium. Thrombolysis is indicated in all patients of acute transmural myocardial infarction presenting within the therapeutic window and have no contraindication to this type of therapy. Beyond the acute phase, ventricular remodeling is influenced most by infarct artery patency, ventricular loading conditions, neurohormonal activation and local tissue growth factors.<sup>14</sup>

### Infarct Artery Patency

Reperfusion may salvage endocardial tissue and restore stunned myocardium in the infarct border zone. Reperfused infarct with contraction-band necrosis may have greater tensile strength and fewer propensities to expansion. However, infarct size, location and collateral flow determine the likelihood of late remodeling.

Several studies have demonstrated a benefit from myocardial reperfusion, with reduced infarct size and associated improvement in regional and global ventricular function.<sup>14</sup> The independent prognostic importance of infarct-related artery patency has emerged from studies in which patency has correlated closely with change in left ventricular volume and function. Use of novel Gp IIb/IIIa platelet inhibitors to preserve the capillary

microcirculation and minimize plugging from the aggregation of platelets, monocytes and macrophages in combination with early restoration of flow to the infarct zone by primary angioplasty or thrombolysis (open artery hypothesis) might further improve myocyte salvage and limit remodeling.

### Pharmacological Interventions

Once infarct evolution has occurred, pharmacological intervention may minimize infarct expansion and ventricular dilatation and improve the long term prognosis.

### Nitroglycerine

Intravenous nitroglycerin limits infarct size, infarct expansion, infarct-related complications and mortality for up to one year.<sup>15</sup> The long-term beneficial effects of transdermal nitroglycerin on left ventricular remodeling after myocardial infarction have also been reported.<sup>16</sup>

### ACE Inhibitors

The efficacy of ACE inhibitors in attenuating left ventricular dilatation after myocardial infarction was first demonstrated in the rats and this effect on remodeling was associated with improved survival.

A recent systematic overview of data from five long term randomized trials showed an overall 28% reduction in death, myocardial infarction and hospital admission for heart failure in patients with position fraction left ventricular dysfunction treated with ACE inhibitors.<sup>17,18</sup>

Activation of the renin angiotensin system in the first few days after acute myocardial infarction can increase the heart rate and systemic vascular resistance and decrease coronary artery perfusion, thus leading to infarct expansion. This could account for the early benefits of ACE inhibitors observed in the fourth international study of infarct survival.

The mechanism of ACE inhibitor action is due in part to peripheral vasodilation, neurohumoral effects and the attenuation of ventricular dilatation. There may be additional benefits for the coronary circulation and intrinsic plasminogen activating system. ACE inhibitors may act directly on myocardial tissue preventing the inappropriate growth and hypertrophy stimulated by angiotensin

II. They may also reduce the number of ischemic events, as suggested by data from the studies of left ventricular dysfunction (SOLVD) and survival and ventricular enlargement (SAVE).<sup>17</sup> Patients with postinfarction left ventricular dysfunction or heart failure should be treated with ACE

inhibitors without delay. Alternatively all patients should be treated with ACE inhibitors initially and therapy continued depending on subsequent assessment of left ventricular function.

### Angiotensin Receptor Blockers

ELITE II study<sup>19</sup> demonstrated that losartan, an angiotensin receptor blocker, shows a survival benefit to the same degree as captopril, an angiotensin converting enzyme inhibitor, does in patients with heart failure. However, recent OPTIMAAL study showed that clinical outcomes after losartan are not superior to those after captopril in patients with AMI.

### $\beta$ -Blockade

The effects of  $\beta$ -blockade on postinfarction left ventricular remodeling have been little studied. Preliminary data suggest that carvedilol may attenuate remodeling, an effect associated with a significant reduction in subsequent adverse cardiac events.<sup>21</sup> The effects of ACE inhibition and  $\beta$ -blockade seem complementary. After myocardial infarction and in chronic heart failure, ACE inhibition improves remodeling and primary reduces deaths from progressive heart failure. In chronic heart failure caused by ischemia,  $\beta$ -blockade with carvedilol can reverse remodeling, which may progress despite standard treatment, including ACE inhibition.<sup>22</sup> The mortality benefit from  $\beta$ -blockade in chronic heart failure, which is now clearly established, is due to a reduction in both progressive heart failure and sudden death. Thus, in patients with significant left ventricular dysfunction or heart failure after myocardial infarction, combination neurohormonal blockade may be optimal, although occasionally limited by hypotension.

The mechanism behind the ability of  $\beta$ -blockade to decrease mortality in chronic heart failure is thought to involve the combination of an antiarrhythmic effect and improved hemodynamic function of the left ventricle, itself caused by a slower heart rate and inhibition of the detrimental

neurohumoral activation virtually always present in chronic heart failure.

It has been suggested that  $\beta$ -Blockade benefits patients with a wide range of resting baseline heart rates, and not only those with evidence of sympathetic hyperactivation. It has also been suggested that long term  $\beta$ -Blockade in heart failure improves left ventricular contractility and mechanical work without increasing myocardial oxygen consumption. Other mechanisms include improved diastolic function, direct protection of myocytes against excess catecholamines and improved regional wall motion.  $\beta$ -Blockers may also have a favorable effect on hibernating myocardium caused by imbalance between myocardial oxygen supply and demand.

Carvedilol, metoprolol and bisoprolol added to standard therapy including an ACE inhibitor have reduced mortality and morbidity in large-scale studies of ischemic and nonischemic heart failure. Metoprolol and bisoprolol are selective  $\beta_1$ -adrenoceptor blockers. Carvedilol is a nonselective,  $\beta_1$ -adrenergic receptor antagonist that also blocks  $\alpha_1$ -adrenoceptors, providing more comprehensive neurohumoral antagonism. It is also a potent antioxidant and thus may prevent the loss of cardiac myocytes that occurs in heart failure as a result of oxidative stress.<sup>21,22</sup>

In patients on long-term treatment after acute myocardial infarction complicated by left ventricular systolic dysfunction, carvedilol reduced the frequencies of all cause and cardiovascular mortality and recurrent nonfatal myocardial infarctions. The reduction in all cause mortality was additional to the effects of ACE inhibitors and re-perfusion therapy.

Thus, the effects of ACE inhibition and  $\beta$ -Blockade appear complementary and both decrease mortality from progressive heart failure. ACE inhibition also controls remodeling while  $\beta$ -Blockade improves myocardial performance and lowers the risk of sudden death. In summary, in significant left ventricular dysfunction or heart failure after myocardial infarction, combined neurohumoral blockade may be optimal, although occasionally limited by hypotension.

### **Synchronized Biventricular Pacing:**

Cardiac resynchronization therapy (CRT) employs atrial sensed synchronous biventricular pacing with

optimization of the atrioventricular delay to trigger ventricular contraction immediately following atrial systole. It prolongs left ventricular filling time, and particularly restore interventricular and intraventricular activation and contraction towards normal. One-third of patients with clinical systolic heart failure have prolonged intraventricular conduction as evidence by increased electrocardiographic QRS duration. Prolonged intraventricular conduction causes major changes in the cardiac periods within the cardiac cycle and it associated with decreased survival.<sup>23</sup>

Importantly, CRT did not simply attenuate progressive LV dilatation such as that which occurs with ACE inhibitor or ARB therapy, but resulted in decreased ventricular volumes below baseline values, consistent with reverse remodeling.<sup>24</sup>

### **Future Clinical Research and Management:**

Ventricular remodeling can be considered a primary target for treatment and a reliable surrogate for long term outcomes. The future challenge must be the primary prevention of myocardial infarction in patients at a high risk for coronary disease. In addition, new therapeutic strategies should be targeted to limit remodeling by the controlled modulation of the molecular and cellular factors involved in tissue repair, including hypertrophy, fibrosis and the capillary microcirculation.

Cardiac remodeling may be defined as expression of the genome in molecular, cellular and interstitial changes that are manifested clinically as changes in the size, shape and function of the heart after cardiac injury. The process is influenced by hemodynamic load, neurohumoral activation and other factors still under investigation.

### **Reference:**

1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. *Circulation* 1990;81:1161-1172.
2. Warren SE, Roy LA, HD' Markis JE, et al. Time course of left ventricular dilatation after myocardial infarction: influence of infarct-related artery and success of coronary thrombolysis. *J Am Coll Cardiol* 1988 ; 11 : 12- 19.
3. Erlebacher JA, Weiss JL, Weisfeldt ML, et al. Early dilatation of the infarcted segment in acute transmural myocardial infarction: role of infarct expansion in acute left ventricular enlargement *J Am Coll Cardiol* 1984;4:201-208.

4. Cleutjens JP, Kandala J, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. *J Mol Coll Cardiol* 1995;27:1281-1292.
5. Lew WYW, Chen Z, Guth B, et al. Mechanisms of augmented segment shortening in nonischemic areas during acute ischemia of the canine left ventricle. *Circ Res* 1985;56:351-358.
6. Hall C. Interaction and modulation of neurohormones on left ventricular remodeling. In: St. John Sutton MG, ed. Left ventricular remodeling after acute myocardial infarction. London : Science Press Ltd; 1996:89-99.
7. Ju H, Zhao s, Tappia PS, et al. Expression of Gq alpha and PLC-beta in scar and border tissue in heart failure due to myocardial infarction. *Circulation* 1998;97:892-829.
8. Bogoyevitch MA, Glennon PE, Anderson MB, et al. Endothelin -1 and fibroblast growth factors stimulate the mitogen – activated protein kinase signaling cascade in cardiac myocytes: the potential role of the cascade in the integration of two signaling pathways leading to myocytes hypertrophy. *J Biol Chem* 1994;269:1110-1119.
9. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac fibroblasts: critical role of the AT1 receptor subtype. *Circ Res* 1993;413-423.
10. Mann DL, Spinale FG. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. *Circulation* 1998;98:1699-1702.
11. Sigusch HH, Campbell SE, Weber KT. Angiotensin II induced myocardial fibrosis in rats: role of nitric oxide.....
12. Levin ER, Gardner DG, Samson WK. Mechanisms of disease: natriuretic peptide, *N Engl J Med* 1998;339:321-328.
13. Sun Y, Cleutjens JR, Diaz-Arias M, et al. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. *Cardiovasc Res* 1994; 28:1423-1432.
14. Marino P, Zanolla L, Zardini P (GISSI)- Effect of streptokinase on left ventricular modeling and function after myocardial infarction: GISSI trial. *J Am Coll Cardiol* 1989;14:1149-1158.
15. Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion and complications: effect of timing, dosage and infarct location. *Circulation* 1988;78:906-919.
16. Mahmarian JJ, Moye LA, Chinov DA. et al. Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective, randomized, double-blind, placebo controlled trial. *Circulation* 1998;97:2017-2024.
17. Pfeffer MA, Braunwald E, Moye' LA, et al on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. *N Eng J Med* 1992;327:669-677.
18. The Acute Infarction Ramipril Efficacy(AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. *Lancet* 1993;342:821-328.
19. Pitt B, Poole -Wilson PA, Segal R, e t al. Effect of Losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival study ELITE II. *Lancet* 2000;355:1582-1587.
20. Dickstein K, Kiekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. *Lancet* 2002;360: 752-60.
21. Basu S, Senior R, Raval Il, et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction: a placebo-controlled, randomized trial. *Circulation*. 1997;96:183-191.
22. Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease: Australia-New Zealand Heart Failure Research Collaborative Group. *J Am Coll Cardiol* 1997;29:1060-1066.
23. Silver H, Amin J, Padmanabhan S, et a. Prognostic implications of increased QRS duration in patients with moderate and severe left ventricular systolic I dsvfunction. *Am J Cardiol* 2001;88:182- 185.
24. Saxon LA, De Marco T, Schafer J et al. Effects of long term biventricular stimulation for resynchronization on echocardiographic measures of remodeling. *Circulation* 2002;105:1304-1310.